Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

Informed consent form signed.
Patients with histopathological diagnosis of mammary cancer who have received neoadjuvant therapy and are candidate, either for tumorectomy, or for mastectomy with complete axillary node dissection,
Informed consent form signed.
Patients with histopathological diagnosis of mammary cancer who have received neoadjuvant therapy and are candidate, either for tumorectomy, or for mastectomy with complete axillary node dissection,

Exclusion Criteria

Diagnosis of mammary cancer established, either by tumorectomy, or by "gross" biopsy,
During the 2 weeks before the enrolment, concurrent medication which reduces or increases the extinction of ICG (i.e. anticonvulsants, haloperidol and Heparin).
Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or disseminated autonomies of the thyroid gland.
...
Diagnosis of mammary cancer established, either by tumorectomy, or by "gross" biopsy,
During the 2 weeks before the enrolment, concurrent medication which reduces or increases the extinction of ICG (i.e. anticonvulsants, haloperidol and Heparin).
Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or disseminated autonomies of the thyroid gland.
Pregnancy, breastfeeding
Advanced renal impairment (creatinine > 1,5mg/dl).
Inability to give informed consent.
Age less than18 years old.
Documented coronary disease.
History of allergy or hypersensitivity against the investigational product (its active substance or ingredients), to iodine or to shellfish.

Summary

Conditions
Breast Cancer
Type
Interventional
Phase
Phase 2
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Diagnostic

Participation Requirements

Age
Between 18 years and 125 years
Gender
Only females

Description

In the operating room: ICG 0.25 mg/kg will be given as an iv injection at least 20 minutes before the beginning of the operation. Optionally, dynamic NIR imaging centered on the tumor bearing breast will be acquired during the 15 minutes after injection (in comparison with standards of known fluores...

In the operating room: ICG 0.25 mg/kg will be given as an iv injection at least 20 minutes before the beginning of the operation. Optionally, dynamic NIR imaging centered on the tumor bearing breast will be acquired during the 15 minutes after injection (in comparison with standards of known fluorescence intensity). Optionally and in case of tumorectomy, peroperative "in vivo" imaging of the surgical dissection will be acquired. The tumour and/or the mammary piece (and the axillary piece) of dissection will be directly imaged "ex vivo" using the PDE camera (in comparison with standards of known fluorescence intensity). In the Laboratory of Pathology: The fresh mammary piece will be processed as usual, but the "gross-thick" sections will be imaged using the PDE and the fluorescent areas will be defined (and later analyzed in comparison with standards of known fluorescence intensity). After fixation, the tumoral tissues as well as - if identified - non tumoral fluorescent foci will be thereafter processed "as usual". All the slides obtained will be analyzed using the NIR fluorescent microscope for the presence or not of detectable ICG and the ICG-positive tissues or compartments (vascular spaces, interstitial spaces, normal and/or tumoral cells, macrophages…) will be determined. If fluorescent foci are identified at the level of the axillary piece, they will be isolated and analyzed like the other lymph nodes. Using the NIR fluorescent microscope, these isolated macroscopically fluorescent structures will be analyzed (lymph node? Other?). Additionally, metastatic lymph nodes will also be controlled for their microscopic fluorescence or not.

Inclusion Criteria

Informed consent form signed.
Patients with histopathological diagnosis of mammary cancer who have received neoadjuvant therapy and are candidate, either for tumorectomy, or for mastectomy with complete axillary node dissection,
Informed consent form signed.
Patients with histopathological diagnosis of mammary cancer who have received neoadjuvant therapy and are candidate, either for tumorectomy, or for mastectomy with complete axillary node dissection,

Exclusion Criteria

Diagnosis of mammary cancer established, either by tumorectomy, or by "gross" biopsy,
During the 2 weeks before the enrolment, concurrent medication which reduces or increases the extinction of ICG (i.e. anticonvulsants, haloperidol and Heparin).
Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or disseminated autonomies of the thyroid gland.
...
Diagnosis of mammary cancer established, either by tumorectomy, or by "gross" biopsy,
During the 2 weeks before the enrolment, concurrent medication which reduces or increases the extinction of ICG (i.e. anticonvulsants, haloperidol and Heparin).
Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or disseminated autonomies of the thyroid gland.
Pregnancy, breastfeeding
Advanced renal impairment (creatinine > 1,5mg/dl).
Inability to give informed consent.
Age less than18 years old.
Documented coronary disease.
History of allergy or hypersensitivity against the investigational product (its active substance or ingredients), to iodine or to shellfish.

Locations

Brussels, 1000
Brussels, 1000

Tracking Information

NCT #
NCT02032563
Collaborators
Not Provided
Investigators
  • Principal Investigator: Isabelle Veys, MD Surgeon in Jules Bordet Institute
  • Isabelle Veys, MD Surgeon in Jules Bordet Institute